Evaluation of the efficiency of peptide receptor radionuclide therapy in patients with metastatic prostate carcinoma
Authors:
Open Access
- 30 April 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (17) , e25612
Abstract
Background: Metastatic prostate carcinoma has poor prognoses with a median survival period ranging from 2 to 5 years with existing therapeutic challenges. Currently, peptide receptor radionuclide therapy is permitted as a treatment method for metastatic prostate carcinoma patients. Therefore, it is crucial to comprehend the efficiency and safety of peptide receptor radionuclide therapy among this patient population. This study aims to analyse the efficacy of peptide receptor radionuclide therapy when used to treat metastatic prostate carcinoma patients. Methods: This research will perform a methodological search in the following electronic databases to find related randomized controlled trials: Cochrane Library, EMBASE, PubMed, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), WanFang database, and Chinese BioMedical Literature. All the databases are searched from their inauguration till November 2020. Two independent authors will screen and select literature for review. The two authors will independently utilize the Cochrane Risk of Bias tool to assess the bias risk in studies. This study also plans to conduct subgroup and sensitivity analyses to evaluate the robustness in the results. Statistical analyses will be conducted with the RevMan 5.3 software. Results: A high-quality synthesis of existing evidence related to peptide receptor radionuclide therapy in the treatment of metastatic prostate carcinoma will be presented in this study. Conclusion: Our findings will provide evidence to judge whether peptide receptor radionuclide treatment is efficient for metastatic prostate carcinoma patients. Ethics and dissemination: An ethics approval is not required because the data of the present study are primarily obtained from published studies. OSF registration number: December 1, 2020.osf.io/3psx7. (https://osf.io/3psx7/).Keywords
Funding Information
- Zhuhai Science and Technology Plan Medical and Health (20181117E030039)
This publication has 14 references indexed in Scilit:
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate CancerFrontiers in Oncology, 2019
- Recent Advances in Prostate-Specific Membrane Antigen-Based RadiopharmaceuticalsCurrent Topics in Medicinal Chemistry, 2019
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision OncologyEuropean Urology, 2019
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Prostate cancer relevant antigens and enzymes for targeted drug deliveryJournal of Controlled Release, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancerCancer, 2010
- The Current State of Hormonal Therapy for Prostate CancerCA: A Cancer Journal for Clinicians, 2002
- Prostate-specific membrane antigen expression in normal and malignant human tissues.1997